Upsher-Smith partners with Cove to expand access to Tosymra for migraine
Upsher-Smith is partnering with Cove, a telemedicine company focused entirely on migraine, to expand access to Upsher-Smith’s non-oral acute migraine medication, Tosymra (sumatriptan nasal spray) 10 mg.
The medication will now be offered through Cove’s telemedicine platform as a treatment option for eligible patients, particularly those who may not have easy access to specialized migraine care. Tosymra is indicated for the acute treatment of migraine with or without aura in adults.
[Read more: Upsher-Smith expands access Pathways Program for commercially insured]
“Upsher-Smith is continually looking for ways to make migraine medications more accessible and affordable for patients,” said Rusty Field, president and CEO, Upsher-Smith. “There’s no question that the number of patients utilizing telemedicine services during the pandemic increased dramatically. Telemedicine served as a critical tool for migraine patients and will continue to play an important role in migraine care, particularly for those who live in areas where it is difficult to see a headache specialist. We are pleased to be able to offer these patients and others, access to Tosymra through Cove.”
Cove connects migraine patients with an independent, licensed healthcare provider who can manage their migraine care and help identify the best treatment option.
Eligible commercially insured patients may pay as little as $0 for Tosymra and receive free home delivery when their prescription is filled through Blink Pharmacy Plus, Upsher-Smith’s partner pharmacy and a leading patient access solution.
[Read more: Q&A: Upsher-Smith CEO on operating during pandemic]
“More than 80% of our patients turn to Cove because they do not have access to specialized migraine care,” added Caroline Hofmann, general manager of Cove. “Our telemedicine platform matches each patient with a doctor who focuses on migraine, who will create a personalized migraine treatment plan and work to determine which products are right for an individual’s needs. We are pleased to add Tosymra to our offering of treatment options, particularly for those who otherwise may not have been able to access this important prescription migraine medication.”